206 results
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
6 Sep 24
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Completes Debt Settlements
9:22pm
market practice for a transaction of this nature and was reasonable and necessary to improve the Company’s financial position in a timely manner
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
30 Aug 24
Current report (foreign)
9:46am
relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company
6-K
EX-4.3
QNTM
Quantum BioPharma Ltd
26 Aug 24
Current report (foreign)
6:04pm
to the Lender, an officer’s certificate specifying the nature of the event requiring the adjustment or readjustment and the amount of the adjustment
6-K
EX-4.4
QNTM
Quantum BioPharma Ltd
26 Aug 24
Current report (foreign)
6:04pm
and obligations of the Obligor of any and every kind, nature or description whatsoever (whether direct or indirect, joint or several or joint and several
6-K
EX-4.1
QNTM
Quantum BioPharma Ltd
26 Aug 24
Current report (foreign)
6:04pm
” means rights of integrity, rights of attribution and other rights of an analogous nature which may now exist or which may exist in the future under … %.
“Tax” means all forms of taxes, duties, imposts, charges, withholdings, rates, levies or other governmental impositions of whatever nature
6-K/A
EX-99.2
cn2ux
19 Aug 24
Condensed consolidated interim financial statements
5:18pm
6-K/A
EX-99.1
l1zbrzad10gpynh ij1
19 Aug 24
Condensed consolidated interim financial statements
5:18pm
6-K
EX-99.1
pwokuvhj4ygeu
14 Aug 24
Condensed consolidated interim financial statements
6:13am
6-K
EX-99.2
jgtl8er
14 Aug 24
Condensed consolidated interim financial statements
6:13am
6-K
EX-99.1
muf5vpx
9 Aug 24
Current report (foreign)
7:30am
6-K
EX-99.1
novee06ayup
29 Jul 24
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
9:04pm
6-K
EX-99.1
43kpwn
8 Jul 24
Annual General and Special Meeting of the Shareholders to Be Held on Management Information Circular
5:16pm
6-K
EX-99.2
e2hu4kflqlyc bqr
8 Jul 24
Amended and Restated Material Change Report
3:20pm
6-K
EX-99.1
ny0 dm1qx2yn
28 Jun 24
FSD Pharma provides Corporate Update
5:01pm
6-K
EX-99.1
mw9f5 kx8hld9en
28 Jun 24
Current report (foreign)
7:49am
6-K
EX-99.1
w3m1t2dslayw s4
27 Jun 24
Current report (foreign)
7:34am
6-K
EX-99.1
jwil7
13 Jun 24
Current report (foreign)
7:31am
6-K
EX-99.1
yna3 wzdk
4 Jun 24
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd™ in Acute Alcohol Intoxication
8:28am
6-K
EX-99.1
hp9zze
31 May 24
Current report (foreign)
7:30am
6-K
EX-99.1
owaaa0af7df
28 May 24
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd™ in Acute Alcohol Intoxication
8:15am